What type of new anti-cancer drug does Datopotamab belong to?

Datopotamab (Datopotamab) is a new type of antibody drug conjugate (Antibody-Drug Conjugate, ADC), which belongs to the category of targeted therapy. It is composed of monoclonal antibodies and cytotoxic drugs combined through chemical linkers. It can specifically recognize targets on the surface of tumor cells and accurately deliver cytotoxic drugs into cancer cells, thus improving the efficiency of the drug in killing tumors while reducing damage to normal cells.

Specifically, dedabrotuzumab targets the Trop-2 protein that is highly expressed on the surface of tumor cells. The expression of this protein is abnormally increased in a variety of solid tumors (such as non-small cell lung cancer, breast cancer, etc.). By combining Trop-2, dabrotuzumab can effectively deliver cytotoxic drugs into tumor cells, release cytotoxic components, and trigger tumor cell apoptosis, thereby achieving anti-tumor effects.

As an antibody-drug conjugate, dedabrotomab combines the high specificity of antibodies with the powerful lethality of traditional chemotherapy drugs. This dual mechanism of "targeting + cytotoxicity" has significantly improved the accuracy and safety of treatment, and is an important direction in the research and development of anti-cancer drugs in recent years. ADCThe development of drugs has provided new treatment options for some tumor types for which traditional treatments have limited effects.

To sum up, dedabrotomab belongs to a new class of targeted anti-cancer drugs called antibody drug conjugates (ADC), which focus on accurately delivering cytotoxic drugs to kill tumor cells by targeting the Trop-2 protein. Its unique mechanism of action and good clinical potential make it show broad application prospects in the treatment of multiple solid tumors.

Reference materials:https://www.drugs.com/